Caplin Point Laboratories’ subsidiary -- Caplin Steriles has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its injectable and ophthalmic manufacturing unit located near Chennai. The unit underwent an inspection from USFDA during May 22- May 31 and the inspection classification was determined by the agency as Voluntary Action Indicated (VAI).
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
